Obesity Featured Articles

  1. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  2. Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy 7/27/2026

    With the help of Beroe Inc.'s Surya Ponnam, discover how per-patient cost (PPC) analytics is evolving into a core capability for balancing cost, quality, speed, and patient outcomes.

  3. Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients 7/24/2026

    CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

  4. Decentralized Trials Still Need Connected Support 7/23/2026

    Decentralized and hybrid trials reduce travel burdens but add coordination challenges. Strong support improves communication, engagement, and smooth trial execution from enrollment to completion.

  5. Make GCP Training Easier For Sites Before Meetings 7/23/2026

    Completing GCP training before investigators’ meetings reduces compliance work, aligns site expectations, and frees meeting time for protocol planning and study startup preparation.

  6. Why Protocol Complexity Is Slowing First Patient In — And How Small Sponsors Can Fix Start-Up Inefficiencies 7/23/2026

    Protocol complexity directly affects timelines, costs, and execution quality. Consultant Jessica Cordes explains why this challenge requires sponsors to change their approach to protocol design, feasibility, and start-up.

  7. Delays At The Handoff: Where Breakdowns Occur Among The Sponsor, CRO, And Site 7/23/2026

    Consultant Jason C. Bork identifies 10 of the most common points at which a trial can break down before and after patient recruitment.

  8. Investigator Perspectives On What Matters In Obesity And GLP-1 Studies 7/22/2026

    Retention, body composition, maintenance therapy, amylin combinations, and behavioral support are reshaping obesity trials. Learn how sponsors can reduce dropout risk and strengthen clinical data.

  9. When One Trial Leads To Rethinking Them All 7/22/2026

    A chance observation during the COVID-19 pandemic led physician-scientist Dan Nicolau to question one of clinical research's oldest assumptions. I spoke with Nicolau about the trial that changed his perspective and why he believes continuous trial analytics could reshape the future of clinical development.

  10. The U.S. Clinical Trial Recruiting Pipeline Report – June 2026 7/22/2026

    This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from May 1 to June 30, 2026.